Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | LIPC | P11150 | 1/20 | 0.35 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5522743 | 0.88 | TRPM8 (0.46) | F2RL3SMN1; SMN2ALDH1A1DHODH | |
| SCHEMBL5522334 | 0.87 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1DHFRACMSD | |
| SCHEMBL5521998 | 0.84 | HCAR2 (0.46) | CHRM4SMN1; SMN2ALDH1A1 | |
| SCHEMBL5527759 | 0.83 | DHFR (0.48) | SMN1; SMN2ALDH1A1LIPGDHFR | |
| SCHEMBL5520170 | 0.82 | KMT2A (0.46) | SMN1; SMN2DHFR | |
| SCHEMBL5528442 | 0.78 | NR1H4 (0.43) | SMN1; SMN2DHFR | |
| SCHEMBL5522256 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL5528655 | 0.78 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL5527532 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL5522180 | 0.77 | HCAR2 (0.46) | CHRM4SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108565-A1 | PYRROLE CARBOXYLIC ACID DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108565-A1 | PYRROLE CARBOXYLIC ACID DERIVATIVES AS ANTIBACTERIAL AGENTS | POLI, POLB, POLA1 | CHRM4 1861/4885F2RL3 1251/4885SMN1; SMN2 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.